Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review

SeyedAlinaghi, SeyedAhmad; Mirzapour, Pegah; Dadras, Omid; Pashaei, Zahra; Karimi, Amirali; MohsseniPour, Mehrzad; Soleymanzadeh, Mahdi; Barzegary, Alireza; Afsahi, Amir Masoud; Vahedi, Farzin; Shamsabadi, Ahmadreza; Behnezhad, Farzane; Saeidi, Solmaz; Mehraeen, Esmaeil; Jahanfar, Shayesteh

doi:10.1186/s40001-021-00524-8

Cited by 95 publications

(90 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We also encourage future research on specific subgroups with certain underlying conditions, as the most suitable biomakers for those groups might differ from the overall population. At last, various COVID-19 variants are showing different specific outcomes of morbidity and mortality (117). Therefore, we suggest future researchers to update the findings related to systemic inflammatory markers specifically for emerging variants.…”

Section: Discussionmentioning

confidence: 90%

Novel Systemic Inflammation Markers to Predict COVID-19 Prognosis

et al. 2021

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has resulted in a global pandemic, challenging both the medical and scientific community for the development of novel vaccines and a greater understanding of the effects of the SARS-CoV-2 virus. COVID-19 has been associated with a pronounced and out-of-control inflammatory response. Studies have sought to understand the effects of inflammatory response markers to prognosticate the disease. Herein, we aimed to review the evidence of 11 groups of systemic inflammatory markers for risk-stratifying patients and prognosticating outcomes related to COVID-19. Numerous studies have demonstrated the effectiveness of neutrophil to lymphocyte ratio (NLR) in prognosticating patient outcomes, including but not limited to severe disease, hospitalization, intensive care unit (ICU) admission, intubation, and death. A few markers outperformed NLR in predicting outcomes, including 1) systemic immune-inflammation index (SII), 2) prognostic nutritional index (PNI), 3) C-reactive protein (CRP) to albumin ratio (CAR) and high-sensitivity CAR (hsCAR), and 4) CRP to prealbumin ratio (CPAR) and high-sensitivity CPAR (hsCPAR). However, there are a limited number of studies comparing NLR with these markers, and such conclusions require larger validation studies. Overall, the evidence suggests that most of the studied markers are able to predict COVID-19 prognosis, however NLR seems to be the most robust marker.

show abstract

Section: Discussionmentioning

confidence: 90%

Novel Systemic Inflammation Markers to Predict COVID-19 Prognosis

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…At the end of December 2019, cases of a highly contagious infectious disease had been reported in Wuhan, China. 1 , 2 , 3 , 4 , 5 , 6 , 7 Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a new strain of coronavirus and belongs to the Beta coronavirus genus of the Coronaviradae family. Due to the high interpersonal transmission rate, soon SARS‐CoV‐2 spread globally and turned into a global pandemic.…”

Section: Introductionmentioning

confidence: 99%

The clinical outcomes of COVID‐19 in HIV‐positive patients: A systematic review of current evidence

SeyedAlinaghi

MohsseniPour

Barzegary

et al. 2021

Immunity Inflam & Disease

Self Cite

View full text Add to dashboard Cite

Introduction Patients with chronic underlying diseases are more susceptible to coronavirus disease 2019 (COVID‐19) complications. Recent studies showed people living with HIV (PLWH) are not at greater risk than the general population. Few studies have reviewed the impacts of COVID‐19 on PLWH. The purpose of this systematic review was to investigate the impact of COVID‐19 on patients infected with HIV. Methods We executed a systematic search using four databases of PubMed, Scopus, Science Direct, and Web of Science and screened the records in two steps based on their title/abstract and full text. This study follows the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) checklist to elevate the validity and reliability of its results. Results We reviewed 36 studies. The patients' age was above 20 years in all studies. In almost all studies, the inflammatory parameters were reported high. In most of the studies, all HIV patients completely recovered from the COVID 19 infection. Although CD4 count was not recorded in all studies, the minimum level was reported as 12 cells/µl. Conclusion Based on the current review, we concluded that HIV patients at advanced stages (3 or 4) of the disease, whose CD4 counts are low, may show less severe COVID‐19 infection symptoms. Similarly, Interference can reduce the severity of immune reactions and subsequent cytokine storms and consequently mitigate the symptoms. Therefore, in most of the studies, the majority of HIV patients showed no severe symptoms and completely recovered from COVID 19 infection.

show abstract

“…SARS-CoV-2 is able to rapidly genetically diversify and can spread internationally through travellers and cause successive outbreaks. SARS-CoV-2 variants cause the COVID-19 disease with different clinical manifestations, even in populations who have previously been exposed to original viruses ( Zeyaullah et al, 2021 ; SeyedAlinaghi et al, 2021 ; Gautret et al, 2021 ). In this study, we compared the demographics, clinical profile, and outcomes of patients infected with different variants that circulated or continue to circulate in the Marseille area, where three major phases have occurred until June 2021.…”

Section: Discussionmentioning

confidence: 99%